Biocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to accelerate gr...

South Korean shares experienced a significant slump on Friday, poised for their first weekly loss in five weeks, influenced by uncertaintie...

South Korean shares reached a record high on Tuesday. Chipmakers saw gains due to optimism surrounding Micron Technology's upcoming results...

In one of the biggest deals worldwide for a biosimilar brand, Ahmedabad-based Intas agreed to buy Udenyca-the brand name for medication peg...

Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In Ind...

The European Medicines Agency (EMA) will this week give the green light to the treatment developed by U.S. biotech firm Regeneron and Swiss...

Till now, only Gilead's antiviral, remdesivir, is the only COVID-19 treatment that has been approved for use in EU. Japanese regulators app...

The company said the participants in the trial were unvaccinated adults older than 18 years with confirmed exposure to a person with the co...

South Korea, like many countries around the world, banned short-selling to tame markets hit by the pandemic early last year.

Essentially flat year-to-date, a gauge of the sector is the worst-performing in Asia, lagging the region’s benchmark by eight percentage po...

Korea, whose benchmark surged last year and is up 8 per cent in 2021, this week bowed to retail investor pressure and extended the ban on t...

Natco has sought nod for the manufacture and marketing of baricitinib bulk drug and tablets in 1 to 4 mg versions in India. This move may t...

To be fair, the stock market has already embraced technology and pharmaceutical shares that underpin global economic transformation.

His rise is extraordinary and represents a shift in the country’s business elite. While family-run conglomerates touch almost every aspect ...

Buy Biocon at a price target of Rs 880.

If the Celltrion skeptics are right, the stock could have a lot further to drop.

Dr Reddy’s was among the first to race off the blocks with four launches in India about as many years. But things have slowed since.